David Meek
Voorzitter bij ENTASIS THERAPEUTICS HOLDINGS INC.
Vermogen: 60 296 $ op 31-05-2024
Profiel
David D. Meek is een zakenman die aan het hoofd heeft gestaan van 7 verschillende bedrijven en momenteel de functie bekleedt van President & Chief Executive Officer bij FerGene, Inc., Voorzitter van Entasis Therapeutics, Inc. en Voorzitter van Entasis Therapeutics Holdings, Inc. De heer Meek zit ook in de raad van bestuur van Pharmaceutical Research & Manufacturers of America, European Federation of Pharmaceutical Industries & Assns en uniQure NV. In zijn loopbaan was David D. Meek Chief Executive Officer & Director bij Ipsen SA en Voorzitter van Ipsen Pharma SAS (een dochteronderneming van Ipsen SA), President & Chief Executive Officer van Novartis Pharmaceuticals Canada, Inc., Chief Executive Officer bij Ipsen Manufacturing Ireland Ltd., Executive Vice President & President-Oncology bij Baxalta, Inc. en Chief Commercial Officer van Endocyte, Inc. De heer Meek behaalde een bachelorgraad aan de Universiteit van Cincinnati (Ohio).
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
UNIQURE N.V.
0.03% | 31-03-2024 | 12 181 ( 0.03% ) | 60 296 $ | 31-05-2024 |
Actieve functies van David Meek
| Bedrijven | Functie | Begin |
|---|---|---|
| UNIQURE N.V. | Voorzitter | 16-06-2021 |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Voorzitter | 24-06-2019 |
| CULLINAN THERAPEUTICS, INC. | Directeur/Bestuurslid | 15-05-2024 |
| Camping & Education Foundation | Directeur/Bestuurslid | - |
Eerdere bekende functies van David Meek
| Bedrijven | Functie | Einde |
|---|---|---|
| FUSN PHAR | Directeur/Bestuurslid | 04-06-2024 |
| MIRATI THERAPEUTICS | Algemeen Directeur | 07-08-2023 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Voorzitter | 01-07-2022 |
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Algemeen Directeur | 01-03-2021 |
European Federation of Pharmaceutical Industries & Assns
 European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Directeur/Bestuurslid | 01-01-2020 |
Opleiding van David Meek
| University of Cincinnati (Ohio) | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| IPSEN | Health Technology |
| UNIQURE N.V. | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 15 |
|---|---|
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
Ipsen Manufacturing Ireland Ltd.
 Ipsen Manufacturing Ireland Ltd. BiotechnologyHealth Technology Ipsen Manufacturing Ireland Ltd. operates as a biopharmaceutical group dedicated to improving lives through innovative medicines. The company was founded in 1989 and is headquartered in Dublin, Ireland. | Health Technology |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Health Technology |
Novartis Pharmaceuticals Canada, Inc.
 Novartis Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Canada, Inc. manufactures chemicals and pharmaceuticals products. It provides solutions on patients suffering from a variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation, and osteoporosis. The company was founded in 1996 and is headquartered in Dorval, Canada. | Health Technology |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Commercial Services |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Health Technology |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
| Camping & Education Foundation | |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Fusion Pharmaceuticals, Inc.
 Fusion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant in 2014 and is headquartered in Hamilton, Canada. | Health Technology |
